Haemonetics Corp Files 8-K
Ticker: HAE · Form: 8-K · Filed: May 23, 2024 · CIK: 313143
| Field | Detail |
|---|---|
| Company | Haemonetics Corp (HAE) |
| Form Type | 8-K |
| Filed Date | May 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $600 million, $185.5 million, $200.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: HAE
TL;DR
HAE filed an 8-K, no major news yet.
AI Summary
On May 22, 2024, Haemonetics Corporation (HAE) filed an 8-K to disclose a Regulation FD event. The filing does not contain specific financial details or material events beyond the reporting of the filing itself.
Why It Matters
This filing indicates Haemonetics Corporation has made a regulatory disclosure, but without further details, its immediate market impact is unclear.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure without immediate material financial or operational news.
Key Players & Entities
- HAEMONETICS CORPORATION (company) — Registrant
- 001-14041 (company) — Commission File Number
- Massachusetts (company) — State of incorporation
- 04-2882273 (company) — IRS Employer Identification No.
- 125 Summer Street Boston, MA 02110 (company) — Principal executive offices address
- 781 - 848-7100 (company) — Registrant's telephone number
- May 22, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and Financial Statements and Exhibits as of May 22, 2024.
What is Haemonetics Corporation's Commission File Number?
Haemonetics Corporation's Commission File Number is 001-14041.
In which state is Haemonetics Corporation incorporated?
Haemonetics Corporation is incorporated in Massachusetts.
What is the address of Haemonetics Corporation's principal executive offices?
The address of Haemonetics Corporation's principal executive offices is 125 Summer Street, Boston, MA 02110.
What is the earliest event date reported in this filing?
The earliest event date reported in this filing is May 22, 2024.
Filing Stats: 487 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-05-23 06:03:52
Key Financial Figures
- $600 million — ncing that it had priced an offering of $600 million aggregate principal amount of convertib
- $185.5 million — tered into agreements to repurchase for $185.5 million in cash approximately $200.0 million in
- $200.0 million — or $185.5 million in cash approximately $200.0 million in aggregate principal amount of its 0.
Filing Documents
- tm2415391d1_8k.htm (8-K) — 25KB
- tm2415391d1_ex99-1.htm (EX-99.1) — 21KB
- tm2415391d1_ex99-1img001.jpg (GRAPHIC) — 5KB
- 0001104659-24-064437.txt ( ) — 228KB
- hae-20240522.xsd (EX-101.SCH) — 3KB
- hae-20240522_lab.xml (EX-101.LAB) — 33KB
- hae-20240522_pre.xml (EX-101.PRE) — 22KB
- tm2415391d1_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. On May 22, 2024, Haemonetics Corporation issued a press release announcing that it had priced an offering of $600 million aggregate principal amount of convertible senior notes due 2029 in a private offering pursuant to Rule 144A under the Securities Act of 1933, as amended, and that it has entered into agreements to repurchase for $185.5 million in cash approximately $200.0 million in aggregate principal amount of its 0.00% Convertible Senior Notes due 2026 in privately negotiated transactions concurrently with the pricing of the notes in the offering. A copy of the press release is furnished as Exhibit 99.1 and incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release of Haemonetics Corporation dated May 22, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HAEMONETICS CORPORATION Date: May 22, 2024 By: /s/ James C. D'Arecca Name: James C. D'Arecca Title: Chief Financial Officer